Poole, A., Li, Y., Wersall, A., & Poole, A. W. (2019). Small GTPases in platelet membrane trafficking. *Platelets, 30*(1), 31-40. https://doi.org/10.1080/09537104.2018.1535703

Publisher's PDF, also known as Version of record

License (if available): CC BY

Link to published version (if available): 10.1080/09537104.2018.1535703

Link to publication record in Explore Bristol Research

PDF-document

This is the final published version of the article (version of record). It first appeared online via Taylor & Francis at https://www.tandfonline.com/doi/full/10.1080/09537104.2018.1535703. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
Small GTPases in platelet membrane trafficking

Tony G. Walsh, Yong Li, Andreas Wersäll & Alastair W. Poole

To cite this article: Tony G. Walsh, Yong Li, Andreas Wersäll & Alastair W. Poole (2018): Small GTPases in platelet membrane trafficking, Platelets, DOI: 10.1080/09537104.2018.1535703

To link to this article: https://doi.org/10.1080/09537104.2018.1535703

© 2018 Taylor & Francis

Published online: 26 Oct 2018.

Submit your article to this journal

Article views: 113

View Crossmark data
Small GTPases in platelet membrane trafficking

Tony G. Walsh, Yong Li, Andreas Wersäll, & Alastair W. Poole

From the School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, UK

Abstract

Our understanding of fundamental biological processes within platelets is continually evolving. A critical feature of platelet biology relates to the intricate uptake, packaging and release of bioactive cargo from storage vesicles, essential in mediating a range of classical (haemostasis/thrombosis) and non-classical (regeneration/inflammation/metastasis) roles platelets assume. Pivotal to the molecular control of these vesicle trafficking events are the small GTPases of the Ras superfamily, which function as spatially distinct, molecular switches controlling essential cellular processes. Herein, we specifically focus on members of the Rab, Arf and Ras subfamilies, which comprise over 130 members and platelet proteomic datasets suggest that more than half of these are expressed in human platelets. We provide an update of current literature relating to trafficking roles for these GTPases in platelets, particularly regarding endocytic and exocytic events, but also vesicle biogenesis and provide speculative argument for roles that other related GTPases and regulatory proteins may adopt in platelets. Advances in our understanding of small GTPase function in the anucleate platelet has been hampered by the lack of specific molecular tools, but it is anticipated that this will be greatly accelerated in the years ahead and will be crucial to the identification of novel therapeutic targets controlling different platelet processes.

Introduction

Membrane trafficking describes a form of cellular communication involving the movement of cargo (e.g., proteins, lipids or pathogens), within membrane bound vesicles, towards spatially distinct compartments. This is a multistep process involving initial vesicle formation from a donor organelle membrane where cargo is packaged (e.g. trans-Golgi network), movement of this ‘carrier’ vesicle towards an acceptor organelle (e.g. early endosome) and, tether to an acceptor with subsequent membrane fusion allowing release of cargo into the lumen of the target organelle [1]. Classically, two of the principal roles for membrane trafficking are exocytosis and endocytosis, which terminate or initiate at the plasma membrane, respectively. At the heart of these processes is the biosynthetic pathway primarily composed of the endoplasmic reticulum (ER) and Golgi complexes to orchestrate the sorting of correctly folded proteins into vesicles, prior to trafficking to a target organelle. These complex and tightly regulated processes are fundamental to eukaryotic cell function, and as such, the Nobel Prize in Physiology or Medicine 2013 was awarded to three pioneering scientists (Rothman, Schekman & Sütow) who discovered key molecular regulators of vesicular traffic in mammalian cells [2].

Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/iplt.

Correspondence: Tony G. Walsh, School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD, UK. E-mail: tony.walsh@bristol.ac.uk

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords
Endocytosis, exocytosis, GTPase, platelets, trafficking

History
Received 26 June 2018
Revised 13 September 2018
Accepted 30 September 2018
Published online xx xxx xxxx

Membrane Trafficking in Platelets

Platelet activity is no exception to these fundamental trafficking processes since they are critically reliant on exocytosis (secretion) and endocytosis to function effectively. Furthermore, trafficking is essential for vesicle (granule) biogenesis and maturation, which occurs within megakaryocytes (platelet precursors) and platelets, respectively (Figure 1) [3]. Secretion of distinctive cargo from platelets into blood occurs from three secretory granules, α-, dense and lysosomes. Secreted cargo is essential for limiting blood loss following acute/traumatic vessel injury (haemostasis), but can also exacerbate platelet activity in diseased blood vessels, causing occlusive ischaemic tissue damage (thrombosis) [4]. Dense granules (~ 3–8/platelet), are loaded with small signalling elements (ADP, ATP, 5HT, Ca²⁺, Mg²⁺ and polyphosphates), which act as autocrine/paracrine agents to amplify platelet activation [5]. Lysosomes (~ 1–3/platelet) are the least well-studied of platelet granules, but it is accepted that they secrete proteolytic enzymes (cathepsins, β- hexosaminidase) involved in clot remodelling processes [6]. On the other hand, platelet α-granules (~ 50–80/platelet) have been the subject of intensive investigation, mostly notably because of the vast array of cargo (chemokines, coagulation factors, adhesive proteins, antimicrobial peptides, growth factors) they release [7]. It is, therefore, unsurprising that platelets, through secreted cargo, also exhibit functions beyond haemostasis, such as inflammation, angiogenesis and tissue repair [8–10]. This in turn has led to a thorough investigation of the secretory machinery regulating platelet secretion. In particular, the molecular mechanisms of granule fusion with the plasma membrane are well described and require a number of key Soluble N-ethylmaleimide-sensitive factor Attachment protein RExceptor (SNARE) proteins, including vesicle associated membrane protein (VAMP)-8, synaptosome associated protein (SNAP)-
and syntaxin 11 and regulatory proteins such as Munc18b, Munc13-4 and syntaxin binding protein 5 (STXBP5) [11,12].

On the contrary, mechanistic insight into endocytic pathways in platelets are less clearly defined. Interestingly, the concept of endocytosis in platelets was first reported almost 30 years ago, but it has only been in recent years that studies have suggested more critical, functional roles for endocytosis in platelets [13,14]. We have previously reported endocytosis and trafficking of G-protein coupled receptors in platelets via clathrin-dependent pathways [15]. Our understanding of platelet granule biogenesis has been largely inferred from studies on human patients with granule deficiencies (referred to as storage pool deficiency) and related murine models [3]. It is believed that α-granules are derived from the biosynthetic and endocytic pathways, where cargoes are initially packaged within early endosomes before targeting to multi-vesicular bodies (MVBs)/late endosomes from which α-granules mature (Figure 1). The mechanism of dense granule biogenesis is more speculative, but is believed to require input from early endosomes, which may mature in MVBs. It is at this point, that the different granule types appear to mature via distinct machinery. For instance, mutations in the NBEAL2 gene cause grey platelet syndrome (GPS), a disorder characterised by α-granule biogenesis defects, but patients have normal dense granule numbers. Similarly patients with Hermansky-Pudlack syndrome (HPS), have deficiencies in dense granules, but not α-granules [16]. Platelet granule biogenesis, has been the subject of recent review articles where greater detail can be found about this process [3,17].

The purpose of this review was to explore the roles of the Rab, Arf and Ras families of small guanosine triphosphatases (GTPases) with respect to platelet membrane trafficking events (exocytosis, endocytosis and granule biogenesis) and provide speculative arguments on trafficking roles that other platelet expressed GTPases may assume. Categorised on the basis of sequence homology, these three families of GTPases comprise over 130 proteins, which function as molecular switches cycling between an inactive ‘GDP-bound’ form to an active ‘GTP-bound’ form to regulate specific effector proteins which can also function beyond membrane trafficking events. The GTPase activities of these proteins are regulated by two classes of proteins; guanine nucleotide exchange factors (GEFs) which promote the GTP-bound form, whereas GTPase-activating proteins (GAPs) accelerate GTP hydrolysis to inactivate the GTPase [18]. Another key feature of these GTPases are the membrane-targeting sequences within the C-termini of Rab and Ras GTPases and N-termini of Arf GTPases, which control their membrane association and biological activity through lipid modifications [19]. We acknowledge there are other important regulators of vesicle trafficking in platelets, such as cytoskeletal proteins, kinases such as PKCα and PKD2, the large GTPase dynamin and dynamin-related protein 1 that are not discussed here, but we refer the reader to a number of relevant publications [20–25]. We also recommend a recent review on RhoGTPases in platelets, which details roles for specific Rho family members with respect to platelet secretion [26].

The Rab GTPase Family in Platelets
Initially described as Ras-like proteins in the brain (Rab), Rab GTPases make up the most abundant family of small GTPases, comprising almost 70 human members and are often described as master regulators of vesicle trafficking within endocytic and
as a result, Rabs provide specific membrane identity, whilst ensuring that membrane-enclosed cargoes are trafficked to the correct cellular compartments. Based on proteomic studies, human platelets contain over 40 Rab members, with a range of expression levels from highly expressed Rab27B (35,000 copies/platelet) to lowly expressed Rab22 (500 copies/platelet, Figure 2) [28]. A seminal paper by Karniguian et al. in 1993 first described the expression of Rabs 1, 3, 4, 6 and 8 in human platelets, with Rabs 3, 4 and 8 being phosphorylated in response to platelet activation, but the relevance of this modification to platelet vesicle trafficking is unknown [29]. Rabs exist in both soluble and membrane-associated forms, the latter being principally mediated by post-translational modification of geranylgeranylation. This modification to cysteine residues within the C-terminus of the GTPases is catalysed by Rab geranylgeranyl transferase (RGGT), which coordinates with Rab escort proteins (REPs) to guide targeting of the Rab protein to vesicle or plasma membranes [27]. Notably, a naturally occurring mutation in gunmetal mice, which causes a 75% reduction in RGGT activity due to an autosomal recessive mutation, leads to a restricted mouse phenotype causing thrombocytopenia, loss of platelet granule content (both α- and dense granules) and prolonged bleeding times [30,31].

GTP-activated Rabs can specifically interact with numerous effectors, including vesicle tethering and fusion regulators, adaptors, motor proteins, kinases and phosphatases to regulate specific trafficking events [32]. Despite the high abundance of different Rab family members, there are limited functional studies on these GTPases in platelets, which likely reflects the limited availability of reliable pharmacological or molecular tools to target them within the anucleate platelet.

Studies in ashen mice, which lack Rab27A, suggested this Rab GTPase member was important for dense granule secretion and biogenesis, but it was subsequently shown that the genetic background of these mice was responsible for the granule defect [33,34]. Further work by Tolmachova et al. clearly demonstrated that platelets from Rab27B knockout mice (KO) exhibit a 50% reduction in dense granule numbers and impaired dense, but not α-, granule cargo release [35]. Notably, double KO (Rab27A/B−/−) platelets displayed slightly exaggerated dense granule release defects suggesting partial redundancy between isoforms, while reduction of dense granule numbers in Rab27B KO platelets was believed to reflect a packaging defect during megakaryocyte maturation [35]. Griscelli syndrome (GS) is one of the earliest examples of mutations in a Rab gene specifically implicated in human disease, where defects in the RAB27A gene cause partial albinism and hemophagocytic syndrome, characterised by uncontrolled T-cell and macrophage activation due to loss of cytolytic granule secretion [36]. No bleeding defects have been reported in type I GS patients, which is presumably due to compensation by the expression of Rab27B, as described above [1]. GTP-loaded Rab27B (and Rab27A) have been shown to directly interact with the SNARE tethering factor Munc13-4 in platelets, mutations of which cause familial hemophagocytic lymphohistiocytosis (FHL) 3, characterised by loss of lymphocyte cytotoxicity required for immune defence [37]. In these patients, secretion from lytic granules of cytotoxic T cells and natural killer cells is blocked, as these granules fail to properly fuse with the plasma membrane [38]. Interestingly, platelets from FHL3 patients and Unc13Δα/α mice, which lack Munc13-4, have a complete ablation of dense granule secretion, suggesting regulators other than Rab27A/B are also important in facilitating dense granule secretion [39-41]. Also importantly and in contrast to the Rab27B knockout, Munc13-4 deficient platelets have normal granule numbers, suggesting other Rab27 effectors mediate granule packaging or biogenesis. Studies in melanosomes have shown the actin motor protein, myosin Va, can interact with Rab27 to regulate vesicle motility, but mouse platelets lacking myosin Va have no secretion defects [42].

In addition to Rab27 isoforms, Rab8 has been shown to regulate dense granule secretion, through interaction with the tethering factor synaptotagamin-like protein (SLP) 4, suggesting a highly complex and coordinated input from different Rab GTPases to facilitate dense granule release [43]. In the Karniguian paper, Rab8 and Rab6, were also found associated with platelet α-granules, while a study using a
permeabilised platelet system showed that calcium-induced exocytosis of vWF from α-granules requires Rab4 [29,44]. Rab3B directly associated with the calcium binding protein calmodulin, which predominantly localised to the particulate fraction of human platelets, suggesting an association of this GTPase with platelet granules and/or the plasma membrane [45]. In other cell systems, Rab3, Rab26 and Rab37 are found associated with exocytotic vesicles, and based on proteomic expression in platelets (Figure 2), it is, therefore, possible that Rab37 may also have an important role in platelet secretion [27]. Interestingly, a recent study in mast cells identified Rab37 as a negative regulator of degranulation, which formed a complex with Munc13-4 and Rab27 and obscured vesicle docking/priming activity [46]. It would, therefore, be interesting to assess if such a role is assumed by Rab37 in platelets.

Mechanistic insights into endocytic pathways in platelets have also been uncovered. A study by Banerjee et al. revealed that VAMP3 regulates receptor-mediated endocytosis of fibrinogen and transferrin, most likely via a clathrin-dependent mechanism [47]. Notably, the authors also showed that fluid phase pinocytosis of labelled dextran into platelets was only marginally affected in VAMP3–/– platelets, consistent with a previous report suggesting stages in endosomal vesicle trafficking, Rab7A is ‘64 activation or in vivo thrombosis. The mechanism underlying

Figure 3

T. G. Walsh et al.

within the

51

permeabilised platelet system showed that calcium-induced exocy-

tosis [39x765]4

differentially regulates early steps in endocytic trafficking [39x371] (in human (and mouse) platelets and might be suggestive of a node

4

distinct endocytic pathways, presumably through interaction with

4

reported that Rab5 isoforms (A, B and C) differentially regulate

4

this internalised cargo was initially trafficked through Rab4 (early

4

endosomes) positive compartments, before targeting to Rab11 (recy-

4

cling endosomes) and vWF (α-granule) compartments. Beyond pla-

4

telets, Rab5 is another GTPase specifically localised to early

4

endosomes that regulates endocytosis and it has been recently

4

reported that Rab5 isoforms (A, B and C) differentially regulate

4

distinct endocytic pathways, presumably through interaction with
different effectors [49]. These three isoforms are relatively abundant in human (and mouse) platelets and might be suggestive of a node through which internalised material is differentially trafficked in platelets towards recycling or degrading lysosomal compartments (Figure 2). Similarly, a study in CHO cells showed that Rab15 differentially regulates early steps in endocytic trafficking [50]. Regarding ‘later’ stages in endosomal vesicle trafficking, Rab7A is often associated with late endocytic compartments and transport to lysosomes. Rab7B controls endosomal transport to the Golgi complex, but proteomic data only supports expression of Rab7A in platelets (Figure 2) [51]. Additionally, the presence of a Golgi structure in platelets has been recently called into question, as Yadav et al. could only confirm the presence of scattered Golgi proteins, existing as separate structures whose function remained to be determined [52].

In megakaryocytes, downregulation of Rab1B, through loss/haploinsufficiency of the transcription factor, RUNX1, alters early vesicle transport from the endoplasmic reticulum (ER) to the Golgi complex causing a reduction in content of the α-granule protein von Willebrand factor (vWF) [53]. Furthermore, Ninkovic et al. showed that fawn-hooded hypertensive rats which lack Rab38, due to a point mutation in the gene start codon, have no apparent dense granules within megakaryocytes or platelets [54]. A subsequent study in cultured MEG-O1 cells showed that Rab32 and Rab38 non-redundantly regulate dense granule biogenesis and both Rab GTPases were shown to specifically traffic dense granule-containing vesicles to immature, Rab7A positive late endosomal/MVBs [55]. As mentioned, loss of dense granules is a classical feature of HPS, in which patients present with numerous clinical manifestations, including a bleeding diathesis due to loss of secreted ADP [56]. Mutations in 10 human genes are associated with HPS, including the Rab GEFs, HPS1 and HPS4, which specifically regulate Rab32 and Rab 38 activity, thereby highlighting a possible role for Rab GEFs in granule biogenesis [57]. Other regulators of Rab GTPase activity present in platelets include the GEFs; Rab3A-interacting protein (regulates Rab8A and 8B), Rabex-5 (regulates Rab5a), vacuole protein sorting (VPS) 39-like protein (regulates Rab7) and GAPs; RabGAP1 (regulates Rab6), RabGAP1-like (regulates Rab22A) and Rab3GAP1 (regulates all Rab3 isoforms), but there is currently no evidence supporting their functional relevance to trafficking events in platelets [28]. Many questions remain for the field of Rab GTPases in platelet function and membrane trafficking. For instance, is internalised cargo trafficked to α-granules, targeted for lysosomal degradation or simply ‘lost’ within the Golgi or other endosomal compartments in platelets? It would also be interesting to assess the trafficking roles other highly expressed Rab GTPases in platelets, such as Rab10 and Rab14, but at present there is a lack of genetic or pharmacological data to speculate upon these roles (Figure 2).

The Arf GTPase Family in Platelets

The ADP-ribosylation factor (Arf) family of small GTPases comprises six founding members that are separated into three classes largely based on sequence homology: Class I (Arfs 1–3), Class II (Arfs 4–5) and Class III (Arf6). It is now recognised that these Arf proteins form part of a larger family containing over 20 proteins consisting of Arf-like (Arl), Arf-related (Arfrp) and the distally related, secretion-associated and Ras-related (Sar) proteins [58]. Figure 3 details the expression profile for this family in platelets, with the founding Arf members being the most highly expressed and a total of 14 Arf family members have been identified. Similar to Rab GTPases, Arfs are under tight spatial and functional control by GEFs and GAPs, but a distinguishing feature is the myristoylation at the N terminus which brings the GTPase in close contact with the membrane allowing for biological activity [59]. Arf effectors, which include coat proteins involved in endocytosis, membrane tethering, lipid enzymes and scaffold proteins, preferentially bind the GTP-bound form of Arf, but the GDP-bound form can also interact with separate targets to regulate trafficking events [60]. Beyond trafficking-associated functions, the Arf family also plays important roles in cytoskeletal remodelling, cytokinesis and lipid droplet formation [60,61]. Various human diseases with mutations in Arf family proteins have begun to emerge, but to the best of our knowledge there are currently no reports of associated bleeding diathesis.

Of the six Arf proteins, Arf6 has received the most attention for its roles in platelets. Choi et al. first demonstrated that Arf6 is a key element in platelet activation through GPVI- and PAR-mediated signalling [62,63]. Interestingly, Arf6-GTP was the predominant form in resting platelets and the level of this GTP-bound state rapidly decreased upon stimulation of platelets with collagen and convulxin, which is unusual since GTPases more commonly exist in inactive GDP-bound states in resting cells. It is possible that under resting conditions, platelets are undergoing active trafficking events involving Arf6, which is favourably localised to the plasma membrane. Indeed, Arf6-GTP-mediated regulation of phospholipase D and phosphatidylinositol 4-phosphate 5-kinase facilitates structural changes in the plasma membrane, allowing recruitment of coat proteins involved in clathrin-mediated endocytosis [64]. Kanamarlapudi et al. later showed that Arf6 activity was also important for P2Y purinoceptor internalisation and subsequent trafficking events which are critical for the resensitisation and function of these receptors in platelets [65]. Conditional gene knockout of Arf6 in mouse platelets resulted in only a mild platelet phenotype due to a defect in fibrinogen uptake by platelets through integrin αIIbβ3-mediated endocytic trafficking [66]. Deletion of Arf6 specifically enhanced platelet spreading on fibrinogen and accelerated clot retraction, but did not affect murine platelet aggregation, surface αIIbβ3 activation or in vivo thrombosis. The mechanism underlying
the enhanced platelet spreading however was not completely understood and was speculated to result from more rapid recycling of activated αIIbβ3 to and from the surface of Arf6 null platelets [66]. Notably, the earlier study by Choi et al. in human platelets reported defective platelet aggregation with a myristoylated (myr)-Arf6 peptide, which preserved Arf6-GTP upon platelet activation [62]. Importantly, the myr-Arf6 peptide also inhibited fibrinogen endocytosis in human platelets, but it not clear if the functional differences between human and mouse platelets is caused by off-target effects of the myr-Arf6 peptide, or due to fundamental differences between species [66].

Besides Arf6, Arf1 and Arf3 represent the most studied Arf members in other cell systems and are more abundant in platelets than Arf6, sharing 96% sequence identity (Figure 3). Most evidence to date supports identical roles for these GTPases in vesicle transport along the biosynthetic pathway, between the endoplasmic reticulum and Golgi compartments, by recruiting coated vesicles allowing for cargo selection and packaging [61]. It is tempting to speculate critical roles for these Arfs along the biosynthetic pathway of α-granule biogenesis within megakaryocytes, but also for their maturation within platelets. Similar roles have been reported for Sar1, of which the Sar1A isoform is relatively abundant in human platelets [67]. In addition, numerous Arf regulators are present in platelets including the GEFs; GBF1, BIG2, CYH2 and GAPs; ArfGAP1/2, ASAP1/2, GIT1/2 and ARAP1, some of which were found complexed within a phosphatidylinositol triphosphate interactome at the plasma membrane of platelets to coordinate signalling events [28,68]. Notably, work by our group demonstrated that Arf6 also controls exocytic pathways in resting platelets, by restraining dense granule secretion via a direct interaction with the Arf GEF, CYH2 (cytohesin-2), which maintained Arf6 in a GTP-bound state. Following activation, CYH2 was phosphorylated by PKC, leading to a dissociation from and inactivation of Arf6, which facilitated granule secretion [69]. In addition to GEFs/GAPs, protein interactions are likely to regulate Arf activity. One piece of evidence comes from Urban and colleagues who showed that deletion of Pdlim7, a PDZ-LIM family protein, resulted in unbalanced Arf6-GDP/GTP ratios in mice, although the mechanism behind this is not clear [70]. Interestingly, perinatal lethality due to spontaneous systemic thrombosis was reported in these mice. However, mice lacking platelet Arf6 have no reported incidence of spontaneous thrombi suggesting the phenotype in Pdlim7 deficient mice is likely independent of Arf6. Undoubtedly, much further experimental work is required to fully understand the functional roles and regulation of Arfs with respect to trafficking events in platelets.

**The Ras GTPase Family in Platelets**

The Ras sarcoma (Ras) GTPases are the second largest family of the Ras superfamily containing 36 members classically associated with cell proliferation, differentiation and survival, while approximately 30% of all human cancers contain Ras activating...
| Protein | Gene | Alpha | Dense | Lysosome | Effect on granule count/content/secretion | Model | Reference |
|---------|------|-------|-------|----------|-------------------------------------------|-------|-----------|
| Rab27A  | RAB27A | Normal vWF levels, normal P-selectin exposure | Normal count/5HT content | nd | Normal count/5HT content | Ashen mouse (Rab27a−/− global) | Barral et al. (2002) |
| Rab27B  | RAB27B | Normal P-selectin exposure | Reduced count/5HT content, secretion defect-further impaired in Rab27a/b null | nd | Rab27b−/− (global) | Tolmachova et al. (2007) |
| Rab38   | RAB38 | Normal count, and P-selectin exposure | None detected in Megs or Platelets | Normal count | Rab32 siRNA (MEG-01 cells) | Ninkovic et al. (2008) |
| Rab32   | RAB32 | nd | Biogenesis defect in Megs | nd | Rab38 siRNA (MEG-01 cells) | Ambrosio et al. (2012) |
| Rab38   | RAB38 | nd | Biogenesis defect in Megs | nd | Rab38 siRNA (MEG-01 cells) | Ambrosio et al. (2012) |
| Arf6    | ARF6 | Normal count, decreased fibrinogen content | Normal count and secretion | nd | Aρf6<sup>lox/lox</sup> PF4-Cre | Huang et al. (2016) |
| RalA    | RALA | Normal count, and secretion* | Normal count and secretion† | Normal count and secretion | RalA<sup>lox/lox</sup>-PF4-Cre | Wersäll et al. (2018) |
| RalB    | RALB | Normal count, P-selectin exposure defect* | Normal count and secretion† | Normal count and secretion | RalB<sup>lox/lox</sup>-PF4-Cre | Wersäll et al. (2018) |
| R-Ras2  | RRAS2 | GPVI-specific secretion defect | GPVI-specific secretion defect | nd | Rras2<sup>−/−</sup> (global) | Janapati et al. (2018) |

*P-selectin exposure defect markedly enhanced and †mild ATP secretion defect in RalA/B double knockout platelets, ‘nd’ indicates no data available, ‘FHH’ indicates fawn-hooded hypertensive.
mutations [71]. Numerous Ras members are expressed in platelets (Figure 3) and early studies demonstrated that Ras could be activated following platelet stimulation [72,73]. However this did not result in the classical activation of the MAP kinase ERK, as is the case in nucleated cells and the relevance of K-, N- and R-Ras GTPases in platelet function remains unclear. Notably, mutations in four different genes associated with Ras signalling, including K-RAS, are linked to the autosomal dominant disorder, Noonan syndrome (NS) [74]. These patients present with a bleeding diathesis and defects in platelet function have been reported, although K-RAS mutations only account for < 2% of NS patients [75,76]. Interestingly, a recent publication by Janapati et al. demonstrated a role for R-Ras2 (TC21) in GPVI-induced integrin activation, granule secretion and thrombus formation, which acted upstream of Rap1B [77]. Rap1 (A and B) are the most abundantly expressed Ras members in platelets and critical roles with respect to platelet integrin activation and adhesiveness have been established, while for the roles much lower expressed Rap2 (A, B and C) members remain elusive. Zhang and colleagues demonstrated that Rap1B is also important for granule (α- and dense) secretion, although the underlying mechanism is not known [78]. For further information on Rap signalling in platelets, we refer the reader to a recent review by Stefanini and Bergmeier [79].

Of particular relevance to this review are the Ras-like (Ral) GTPases, RalA and RalB. Like most Ras GTPases, Rals have been implicated in numerous cellular processes including oncogenic transformations, but have also been implicated as regulators of vesicle trafficking [80]. They are ubiquitously expressed, with high abundance in brain, testes and platelets sharing 82% sequence identity, with ~ 55% identity to other Ras GTPases [81]. A well-characterised effector of Rals is the exocyst complex, comprising of 8 proteins (EXOC1-8) that facilitate the tethering of exocytic vesicles to the plasma membrane [82]. Notably, all components of this octameric complex are present in human (and mouse) platelets and GTP-loaded Rals have been shown to bind to EXOC2 and EXOC8 in a mutually exclusive manner [83]. Similarly, other established effectors of Rals include Rap binding protein (RalBPI) and phospholipase D, but their relevance to platelet function and/or vesicle trafficking remains to be determined. Of relevance, RalBPI has been shown to play a role in receptor-mediated endocytosis by interacting with epsin homology domain proteins Repl1 and Repl2, as well as clathrin adaptor protein complex AP2, all of which are present in platelets and are supportive of an endocytic function for platelet Rals (Figure 1) [84].

Within platelets, Ral was found associated with dense granules [85] and can be activated by various platelet agonists in a Ca^2+ -dependent manner, while studies in endothelial cells support a role for RalA in Weibel Palade body exocytosis [86,87]. Interestingly, it is well characterised that Rap activity is regulated by numerous Ras GTPases, including H-Ras, R-Ras, Rap 1 (A and B), which directly bind to and regulate Rap GEFs, including RapGDS and RGL (1–3) [88]. Promocytic data analysis only supports the expression of RGL2 in murine platelets, while the RapGAP αI, α2 and β subunits are present in human (and mouse) platelets to regulate Rap-GTP hydrolysis [28,89]. Considering the importance of Rap to platelet secretion, if would be interesting to assess a potential crosstalk between Rap and Ral GTPases. Functional studies involving permeabilised human platelets alluded to a role for Rals in dense granule secretion, through an interaction with EXOC2 [90]. However, a recent study from our group demonstrated that murine platelets lacking either RalA or RalB have no defect in dense granule cargo release, while RalA/B double KO (DKO) platelets have only a marginal defect which does not alter functional responses such as aggregation and thrombus formation [91]. Interestingly, platelet surface exposure of P-selectin in DKO platelets was substantially reduced (by ~ 85%) in response to GPVI-mediated platelet activation, whereas the release of an array of soluble α-granule cargo was unaffected. Notably, this exocytic defect in α-granule release of P-selectin was not due to the minor reduction in secreted ADP from dense granules. This also reveals mutually redundant trafficking roles for both Ral proteins in platelets, which corroborates their roles in development and tumorigenesis [80]. These findings raise intriguing questions regarding exocytic trafficking processes in platelets. Firstly, do ‘kiss-and-run’ secretion events occur, where soluble cargo are readily released upon transient fusion of the secretory vesicle at the plasma membrane? An alternative explanation is the presence of P-selectin positive and negative α-granule subpopulations, as it has been reported to be differentially localised to another α-granule protein, vWF, and thereby Rals could specifically target the P-selectin positive population [92]. Undoubtedly many questions remain regarding theories of cargo storage in platelets and mechanisms controlling their trafficking and release, but these observations reported in Rap deficient platelets offer attractive therapeutic potential [93,94].

Conclusion

It has become increasingly apparent that small GTPases play pivotal roles in the regulation of membrane vesicle trafficking in anucleate platelets as they do in nuclear cells. They shuttle between cytosolic and membrane compartments, and as such they are well positioned to control these critical cellular processes. Our knowledge of these binary molecular switches in platelets has accumulated in the last two decades, particularly through research with genetic manipulation in animal models (see Table 1). Furthermore, platelet proteomic datasets have provided key expression data on an array of small GTPases, whose relevance to platelet function remains to be determined. Crucially, these discoveries may lead to the identification of specific targets that could pave the way for manipulating exocytic and endocytic processes in platelets. For instance, the ability to selectively modulate P-selectin mediated platelet-leukocyte interactions during inflammatory pathologies, without affecting the haemostatic properties of platelets. Reciprocally, it could be possible to selectively control the endocytic uptake of plasma proteins by platelets that could be useful for exploiting tissue regenerative roles for platelets, but also to control the sequestration of tumor proteins by platelets that primes distal sites, such as bone, for metastasis [95].

Disclosure Statement

The authors report no conflict of interest.

Funding

This work was supported by British Heart Foundation (BHF) grants awarded to A.W.P. [FS/14/23/30756,PG/15/16/31854,RG/15/16/31758].

ORCID

Alastair W. Poole http://orcid.org/0000-0002-0868-297X

References

1. Seabra MC, Mules EH, Hume AN. Rab GTPases, intracellular traffic and disease. Trends Mol Med 2002;8:23–30.
2. Ferro-Novick S, Brosé N. Nobel 2013 Physiology or medicine: traffic control system within cells. Nature 2013;504:98. doi:10.1038/504098a
3. Sharda A, Flamenta R. The life cycle of platelet granules. F1000Res 2018;7:236. doi:10.12688/f1000research
4. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938–949. doi:10.1056/NEJMra0801082
Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2000;113:135–138.

Harrison P, Wüllenbörn B, Dehbi N, Vainchenker W, Breton-Gorius J, Lawrie AS, Masse JM, Savidge GF, Cramer EM. Uptake of plasma granules is mediated by αIIbβ3 (glycoprotein IIb-IIIa).

Mundell SJ, Luo J, Benovic JL, Conley PB, Poole AW. Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. Traffic 2006;7:1420–1431. doi:10.1111/j.1600-0854.2006.00469.x

Huizing M, Parkes JM, Helip-Wooley A, White JG, Gahl WA. Platelet alpha granules in BLOC-2 and BLOC-3 subtypes of Hermansky-Pudlak syndrome. J Thromb Haemost 2007;5:194–201. doi:10.1111/j.1538-7836.2006.02690.x

Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378–3384. doi:10.1172/JCI27196

T. G. Walsh et al. Platelets, Early Online: 1.
secretion in platelets. J Biol Chem 2000;275:33844–33849.
doi:10.1074/jbc.2000384200

Safdar BS, Bhullar RP. Rab3B in human platelet is membrane bound and interacts with Car2(+)-calmodulin. Biochem Biophys Res Commun 2001;289:1039–1043. doi:10.1006/ bbrc.2001.6113

Higashio H, Satoh Y, Saino T. Mast cell degranulation is negatively regulated by the Munc13-4-binding small-guanosine triphosphatase Rab37. Sci Rep 2016;6:22539. doi:10.1038/srep22539

Banerjee M, Joshi S, Zhang J, Moncman CL, Yadav S, Bouchard BA, Storrre B, Whiteheart SW. Cellubrevin/vesicle-associated membrane protein-3-mediated endocytosis and trafficking regulate platelet functions. Blood 2017;130:2972–2983. doi:10.1182/blood-2017-02-76176

Behnke O. Degrading and non-degrading pathways in fluid-phase (non-adsorptive) endocytosis in human blood platelets. J Submicrosc Cytol Pathol 1992;24:169–178.

Rastogi R, Verma JK, Kapoor A, Langsly G, Mukhopadhyay A. Rab5 isoforms specifically regulate different modes of endocytosis in Leishmania. J Biol Chem 2016;291:14732–14746. doi:10.1074/jbc.M116.716151

Zuk PA, Elferink LA. Rab15 differentially regulates early endocytic trafficking. J Biol Chem 2000;275:26754–26764. doi:10.1074/jbc.M000344.2000

Guerra F, Bucci C. Multiple roles of the small GTPase Rab7. Cells 2016;5. doi:10.3390/cells5030034

Yadav S, Williamson JK, Aronova MA, Prince AA, Pokrovskaya V, Colletti CM, Whiteheart SW. Arf6 controls platelet spreading and clot retraction via integrin αIIbbβ3 trafficking. Blood 2016;127:1459–1467. doi:10.1182/blood-2015-05-648550

Zhang G, Xiang B, Kanaho Y, Li Z, Bouchard BA, Moncman CL, Whiteheart SW. Arf6 controls platelet spreading and clot retraction via integrin αIIbbβ3 trafficking. Blood 2016;127:1459–1467. doi:10.1182/blood-2015-05-648550

Brandizzi F, Barlowe C. Organization of the ER-Golgi interface for membrane traffic control. Nat Rev Mol Cell Biol 2013;14:382–392. doi:10.1038/nrm35703

Durrant TN, Hutchinson JL, Heesom KJ, Anderson KE, Stephens LW, Hawkins PT, Marshall AJ, Moore SF, Hers I. In-depth PtdIns (3,4,5)P3 signalosome analysis identifies DAPP1 as a negative regulator of GPIb-driven platelet function. Blood Adv 2017;1:918–932. doi:10.1182/bloodadvances.2017005173

don van Bosch MT, Poole AW, Hers I. Cytohesin-2 phosphorylation by protein kinase C relieves the constitutive suppression of platelet dense granule secretion by ADP-ribosylation factor 6. J Thromb Haemost 2014;12:726–735. doi:10.1111/jth.12542

Urban AE, Quick EO, Miller KP, Krcmery J, Simon HG. Pldmill regulates Arf6-dependent active dynamics in platelets. J Thromb Haemost 2016;14:610402. doi:10.1111/jth.14197

Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295–308. doi:10.1038/nrc2109

Tulasee D, Bori T, Watson SP. Regulation of RAS in human platelets. Evidence that activation of RAS is not sufficient to lead to ERK1-2 phosphorylation. Eur J Biochem 2002;269:1511–1517.

Jalagadugula G, Goldfinger LE, Mao G, Lambert MP, Rao AK. ARF6 and Rab37. Sci Rep 2016;6:22539. doi:10.1038/srep22539

Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol 2011;12:368–375. doi:10.1038/nrm3117

Aronova MA, Prince AA, Pokrovskaya V, Colletti CM, Whiteheart SW. Arf6 controls platelet spreading and clot retraction via integrin αIIbbβ3 trafficking. Blood 2016;127:1459–1467. doi:10.1182/blood-2015-05-648550

van Dam EM, Robinson PJ. Ral: mediator of membrane trafficking. Curr Biol 2011;21:347–354. doi:10.1016/j.cub.2011.03.019

Brandizzi F, Barlowe C. Organization of the ER-Golgi interface for membrane traffic control. Nat Rev Mol Cell Biol 2013;14:382–392. doi:10.1038/nrm35703
88. Neel NF, Martin TD, Stratford JK, Zand TP, Reiner DJ, Der CJ. The RalGEF-Ral effector signaling network: the road less traveled for anti-ras drug discovery. Genes Cancer 2011;2:275–287. doi:10.1177/1947601911407329

89. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, Madugundu AK, Kelkar DS, Isserlin R, Jain S, et al. A draft map of the human proteome. Nature 2014;509:575–581. doi:10.1038/nature13302

90. Kawato M, Shirakawa R, Kondo H, Higashi T, Ikeda T, Okawa K, Fukai S, Nureki O, Kita T, Horiuchi H. Regulation of platelet dense granule secretion by the Ral GTPase-exocyst pathway. J Biol Chem 2008;283:166–174. doi:10.1074/jbc.M705340200

91. Wersall A, Williams CM, Brown E, Iannitti T, Williams N, Poole AW. Mouse platelet Ral GTPases control P-selectin surface expression, regulating platelet-leukocyte interaction. Arterioscler Thromb Vasc Biol 2018;38:787–800. doi:10.1161/ATVBAHA.117.310294

92. Zingariello M, Fabucci ME, Bosco D, Migliaccio AR, Martelli F, Rana RA, Zetterberg E. Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation. Biotech Histochem 2010;85:157–170. doi:10.3109/10520290903149612

93. Italiano JE Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111:1227–1233. doi:10.1182/blood-2007-09-113837

94. Jonnalagadda D, Izu LT, Whiteheart SW. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 2012;120:5209–5216. doi:10.1182/blood-2012-07-445080

95. Kerr BA, McCabe NP, Feng W, Byzova TV. Platelets govern premetastatic tumor communication to bone. Oncogene 2013;32:4319–4324. doi:10.1038/onc.2012.447